A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC

Clinical trial NCT06478043 · COMPLETED

Trial details

NCT number: NCT06478043
Sponsor: Zhejiang Cancer Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Extensive-stage Small-cell Lung Cancer

Start date: 2024-10-16
Primary completion: 2024-10-22
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.